Experience with axitinib treatment in mRCC 2nd line patients
dc.contributor.author | Richter Igor | cs |
dc.contributor.author | Dvořák Josef | cs |
dc.date.accessioned | 2020-06-08T09:42:43Z | |
dc.date.available | 10-41-2019 | en |
dc.date.available | 2020-06-08T09:42:43Z | |
dc.date.issued | 2018 | cs |
dc.date.updated | 29-53-2019 | en |
dc.format.extent | 0 | cs |
dc.identifier.uri | https://dspace.tul.cz/handle/15240/155921 | |
dc.language.iso | cze | cs |
dc.relation.ispartofseries | 0 | cs |
dc.subject | axitinib | cs |
dc.subject | Metastatic Renal Carcinoma | cs |
dc.title | Experience with axitinib treatment in mRCC 2nd line patients | en |
dc.title | Zkušenosti s léčbou axitinibem u pacientů ve 2. linii mRCC | cs |
local.identifier.publikace | 6553 |